Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
CGTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $2.95
Previous CloseN/A
Volume950.02K
Average Volume (3M)985.36K
Market Cap
$25.34M
Enterprise Value-$2.49M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 26, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding41,547,997
10 Day Avg. Volume505,443
30 Day Avg. Volume985,358
Standard Deviation0.29
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.89
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$4.00Price Target Upside555.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cognition Therapeutics News
PremiumCompany Announcements
Cognition Therapeutics Shows Promising Phase 2 Study Results
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyCT1812 significantly slows cognitive decline in patients with specific Alzheimer's biomarkers, indicating a strong potential for its effectiveness.
Investor InterestPositive results from the SHIMMER trial should resurrect investor interest in CT1812 and Cognition overall; this may constitute a substantial value inflection point.
Market PotentialDementia with Lewy bodies constitutes a large market niche and could represent a blockbuster or near-blockbuster indication for CT1812 in the U.S. alone.
Bears Say
Clinical RisksRisks include negative clinical data readouts, inability to advance CT1812 into pivotal trials in a timely manner, and failure to generate favorable top-line data from pivotal trials.
Financial PerformanceThe company recorded a net loss of $0.25 per share, substantively wider than forecasted net loss of only $0.16 per share, mainly driven by higher-than-anticipated R&D spending.
Treatment Efficacy VariabilityPatients with p-tau217 above median levels demonstrated similar ADAS-Cog-11 changes from baseline compared to placebo, with CT1812 treatment being slightly worse than placebo.
---
Ownership Overview
33.47% Insiders
3.91% Mutual Funds
20.16% Other Institutional Investors
39.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.34 and its highest was $2.95 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $25.34M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 33 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.053.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 41,547,997 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Among the largest hedge funds holding Cognition Therapeutics’s share is Carlson Capital LP. It holds Cognition Therapeutics’s shares valued at 0.
---
Cognition Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (555.74% Upside)
$4.00 (555.74% Upside)
Blogger Sentiment
Bearish
CGTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 140.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $29.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.85%
12-Months-Change
Fundamentals
Return on Equity
-157.90%
Trailing 12-Months
Asset Growth
-28.87%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
---
CGTX Stock 12 Month Forecast
Average Price Target
$4.00
▲(555.74% Upside)
Technical Analysis
Best Analysts Covering CGTX
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-31.29%
reiterated a buy rating 16 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -31.29% per trade.
---